About Aetna (NYSE:AET)
Aetna Inc. is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers' compensation administrative services and health information technology (HIT) products and services. The Health Care segment consists of medical, pharmacy benefit management services, dental, behavioral health and vision plans offered on both an Insured basis and an employer-funded basis, and emerging businesses products and services. The Group Insurance segment includes group life insurance and group disability products. Its products are offered on an Insured basis.
Industry, Sector and Symbol
Industry MEDICAL CARE
Sub-IndustryManaged Health Care
Trailing P/E Ratio29.8243996946082
Forward P/E Ratio15.55
Sales & Book Value
Annual Sales$60.54 billion
Price / Sales0.93
Cash Flow$12.30 per share
Price / Cash13.98
Book Value$48.46 per share
Price / Book3.55
Net Income$1.90 billion
Return on Equity21.50%
Return on Assets5.87%
Aetna (NYSE:AET) Frequently Asked Questions
What is Aetna's stock symbol?
Aetna trades on the New York Stock Exchange (NYSE) under the ticker symbol "AET."
How often does Aetna pay dividends? What is the dividend yield for Aetna?
Aetna announced a quarterly dividend on Friday, February 23rd. Stockholders of record on Thursday, April 12th will be given a dividend of $0.50 per share on Friday, April 27th. This represents a $2.00 annualized dividend and a dividend yield of 1.16%. The ex-dividend date is Wednesday, April 11th. View Aetna's Dividend History.
How will Aetna's stock buyback program work?
Aetna declared that its board has initiated a stock buyback plan on Friday, April 7th 2017, which allows the company to buyback $4,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 98% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board believes its stock is undervalued.
How were Aetna's earnings last quarter?
Aetna Inc (NYSE:AET) released its earnings results on Tuesday, January, 30th. The company reported $1.25 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.18 by $0.07. The business earned $14.74 billion during the quarter, compared to the consensus estimate of $14.79 billion. Aetna had a return on equity of 21.50% and a net margin of 3.15%. The business's revenue was down 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.08 earnings per share. View Aetna's Earnings History.
When will Aetna make its next earnings announcement?
Where is Aetna's stock going? Where will Aetna's stock price be in 2018?
19 equities research analysts have issued twelve-month price objectives for Aetna's shares. Their forecasts range from $158.00 to $212.00. On average, they expect Aetna's share price to reach $191.69 in the next year. View Analyst Ratings for Aetna.
What are Wall Street analysts saying about Aetna stock?
Here are some recent quotes from research analysts about Aetna stock:
- 1. According to Zacks Investment Research, "Aetna’s third-quarter earnings surpassed the Zacks Consensus Estimate and grew year over year, driven by strong underwriting margin performance, disciplined pricing, a focus on high quality care management, and a decline in medical cost. Aetna’s shares have outperformed the industry year to date. We expect the company to witness long-term growth from its Government business and International expansion. Its cost-reduction initiatives will aid margins. The sale of its Group Life and Disability business will help it to focus on core growth areas. Following strong third-quarter results, Aetna raised its earnings guidance, cementing investors' confidence in it. Aetna has, however, been incurring losses in its public exchange business and has been exiting exchanges. Furthermore, its membership growth remains under pressure. Increasing medical benefit ratios are also likely to hurt margins." (11/2/2017)
- 2. Cantor Fitzgerald analysts commented, "There is life after Humana. CEO Mark Bertolini opened the meeting discussing life after Humana. With a continued focus to grow its government business, Mr. Bertolini indicated that Humana represented a means to an end." Instead, AET will now chose to build its government business organically. We believe the company will also pursue acquisitions to build out its capabilities in specific geographies. CFO Shawn Guertin identified Medicare as a great growth opportunity, but characterized Medicaid as a good opportunity. Growth in Medicaid slowed recently due to two contract losses and potential for structural changes to Medicaid exist." (5/12/2017)
- 3. Royal Bank of Canada analysts commented, "After the close on Monday, April 24, Humana pre-released 1Q17 EPS ahead of its investor meeting, which will be held on Tuesday, April 25. 1Q17 Adjusted EPS for the quarter was $2.75 vs. our estimate of $2.50 and FactSet consensus of $2.49." (4/24/2017)
- 4. Oppenheimer Holdings Inc. analysts commented, "Overall, we believe Humana is well positioned for growth, given the political support in Washington, ample strategic capital to deploy and the potential for upside to its current earnings base."Ultimately, this will also remain a desirable asset that could be acquired by another insurer." (3/31/2017)
Are investors shorting Aetna?
Aetna saw a increase in short interest during the month of February. As of February 28th, there was short interest totalling 4,422,017 shares, an increase of 41.9% from the February 15th total of 3,116,854 shares. Based on an average trading volume of 1,927,662 shares, the days-to-cover ratio is presently 2.3 days. Approximately 1.3% of the shares of the stock are sold short.
Who are some of Aetna's key competitors?
Some companies that are related to Aetna include Anthem (ANTM), Fresenius (FSNUY), Express Scripts (ESRX), Humana (HUM), HCA Healthcare (HCA), Cerner (CERN), Centene (CNC), Quest Diagnostics (DGX), Davita (DVA), Universal Health Services (UHS), Eurofins Scientifi (ERFSF), Nmc Health (NMHLY), WellCare Health Plans (WCG), Icon (ICLR), PRA Health Sciences (PRAH), athenahealth (ATHN), Encompass Health (EHC) and MEDNAX (MD).
Who are Aetna's key executives?
Aetna's management team includes the folowing people:
- Mark T. Bertolini, Chairman of the Board, Chief Executive Officer (Age 60)
- Karen S. Lynch, President (Age 54)
- Shawn M. Guertin, Chief Financial Officer, Executive Vice President, Chief Enterprise Risk Officer (Age 53)
- Thomas J. Sabatino Jr., Executive Vice President, General Counsel (Age 58)
- Margaret M. McCarthy, Executive Vice President - Operations and Technology (Age 63)
- Harold L. Paz M.D., Executive Vice President, Chief Medical Officer (Age 62)
- Francis S. Soistman Jr., Executive Vice President - Government Services (Age 60)
- Heather Dixon, Chief Accounting Officer, Vice President, Controller (Age 45)
- Edward J. Ludwig, Lead Independent Director (Age 65)
- Fernando G. Aguirre, Independent Director (Age 60)
Has Aetna been receiving favorable news coverage?
Media stories about AET stock have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aetna earned a media sentiment score of 0.00 on Accern's scale. They also assigned news headlines about the company an impact score of 45.18 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Aetna's major shareholders?
Aetna's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.39%), Farallon Capital Management LLC (1.60%), Alliancebernstein L.P. (1.08%), Geode Capital Management LLC (1.02%), OppenheimerFunds Inc. (1.00%) and Deutsche Bank AG (0.83%). Company insiders that own Aetna stock include Francis S Soistman Jr, Jeffrey E Garten, Karen S Lynch, Margaret M Mccarthy, Mark T Bertolini and Shawn M Guertin. View Institutional Ownership Trends for Aetna.
Which major investors are selling Aetna stock?
AET stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Alliancebernstein L.P., Fred Alger Management Inc., Lyrical Asset Management LP, Atalanta Sosnoff Capital LLC, Victory Capital Management Inc., Westwood Holdings Group Inc. and Standard Life Aberdeen plc. Company insiders that have sold Aetna company stock in the last year include Karen S Lynch, Margaret M Mccarthy, Mark T Bertolini and Shawn M Guertin. View Insider Buying and Selling for Aetna.
Which major investors are buying Aetna stock?
AET stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Deutsche Bank AG, Alpine Associates Management Inc., Amundi Pioneer Asset Management Inc., Hudson Bay Capital Management LP, CI Investments Inc., Twin Securities Inc. and Manikay Partners LLC. View Insider Buying and Selling for Aetna.
How do I buy shares of Aetna?
Shares of AET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aetna's stock price today?
One share of AET stock can currently be purchased for approximately $171.96.
How big of a company is Aetna?
Aetna has a market capitalization of $56.86 billion and generates $60.54 billion in revenue each year. The company earns $1.90 billion in net income (profit) each year or $5.75 on an earnings per share basis. Aetna employs 47,950 workers across the globe.
How can I contact Aetna?
Aetna's mailing address is 151 FARMINGTON AVENUE, HARTFORD CT, 06156. The company can be reached via phone at 860-273-0123 or via email at [email protected]
MarketBeat Community Rating for Aetna (AET)MarketBeat's community ratings are surveys of what our community members think about Aetna and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aetna (NYSE:AET) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.63||2.63||2.52||2.74|
|Ratings Breakdown: ||0 Sell Rating(s)|
7 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
7 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
10 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$191.69||$191.69||$178.71||$160.63|
|Price Target Upside: ||11.47% upside||2.27% upside||0.05% downside||1.58% downside|
Aetna (NYSE:AET) Consensus Price Target History
Aetna (NYSE:AET) Analyst Ratings History
(Data available from 3/20/2016 forward)
Aetna (NYSE:AET) Earnings History and Estimates Chart
Aetna (NYSE AET) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/30/2018||Q4 2017||$1.18||$1.25||$14.79 billion||$14.74 billion||View||N/A|
|10/31/2017||Q3 2017||$2.06||$2.45||$15.12 billion||$14.99 billion||View||N/A|
|8/3/2017||Q2 2017||$2.34||$3.42||$15.34 billion||$15.52 billion||View||Listen|
|5/2/2017||Q1 2017||$2.36||$2.71||$15.39 billion||$15.17 billion||View||Listen|
|1/31/2017||Q416||$1.44||$1.63||$15.84 billion||$15.73 billion||View||Listen|
|10/27/2016||Q316||$2.02||$2.07||$15.71 billion||$15.78 billion||View||Listen|
|8/2/2016||Q216||$2.12||$2.21||$15.69 billion||$15.95 billion||View||Listen|
|4/28/2016||Q116||$2.23||$2.30||$15.46 billion||$15.69 billion||View||Listen|
|2/1/2016||Q415||$1.21||$1.37||$14.93 billion||$15.09 billion||View||Listen|
|10/29/2015||Q315||$1.77||$1.90||$15.22 billion||$15.00 billion||View||Listen|
|8/4/2015||Q215||$1.82||$2.05||$15.43 billion||$15.13 billion||View||Listen|
|4/28/2015||Q115||$1.96||$2.39||$15.48 billion||$15.09 billion||View||Listen|
|2/3/2015||Q414||$1.22||$1.22||$14.59 million||$14.77 million||View||Listen|
|10/28/2014||Q214||$1.58||$1.79||$14.63 billion||$14.70 billion||View||Listen|
|7/29/2014||Q114||$1.61||$1.69||$13.98 billion||$14.50 billion||View||Listen|
|4/24/2014||Q413||$1.56||$1.98||$13.69 billion||$13.97 billion||View||Listen|
|2/6/2014||Q313||$1.36||$1.34||$13.14 billion||$13.13 billion||View||Listen|
|10/29/2013||Q213||$1.53||$1.53||$12.89 billion||$12.99 billion||View||Listen|
|7/30/2013||Q2 2013||$1.39||$1.52||$12.02 billion||$11.56 billion||View||Listen|
|4/30/2013||Q1 2013||$1.38||$1.50||$9.65 billion||$9.51 billion||View||Listen|
|1/31/2013||Q4 2012||$0.96||$0.94||$8.97 billion||$8.96 billion||View||Listen|
|10/25/2012||Q312||$1.34||$1.55||$8.96 billion||$8.90 billion||View||N/A|
Aetna (NYSE:AET) Earnings Estimates
2018 EPS Consensus Estimate: $11.08
2019 EPS Consensus Estimate: $12.50
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Aetna (NYSE:AET) Dividend Information
|Dividend Growth:||24.80% (3 Year Average)|
|Payout Ratio:||34.78% (Trailing 12 Months of Earnings) |
18.08% (Based on This Year's Estimates)
16.31% (Based on Next Year's Estimates)
Aetna (NYSE:AET) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Aetna (NYSE AET) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.14%
Institutional Ownership Percentage: 87.25%
Aetna (NYSE AET) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|9/18/2017||Karen S Lynch||President||Sell||15,271||$161.91||$2,472,527.61||64,261|| |
|9/15/2017||Margaret M Mccarthy||EVP||Sell||10,288||$162.85||$1,675,400.80||33,563|| |
|6/7/2017||Margaret M Mccarthy||EVP||Sell||27,028||$149.23||$4,033,388.44||33,563|| |
|5/17/2017||Mark T Bertolini||Chairman||Sell||103,547||$140.79||$14,578,382.13||659,888|| |
|3/23/2017||Shawn M Guertin||Insider||Sell||29,602||$129.35||$3,829,018.70||44,880|| |
|3/8/2017||Francis S Soistman Jr||VP||Sell||6,607||$131.98||$871,991.86||23,454|| |
|9/7/2016||Jeffrey E. Garten||Director||Sell||7,100||$116.51||$827,221.00|| |
|8/23/2016||Shawn M Guertin||Insider||Sell||45,328||$120.21||$5,448,878.88||44,883|| |
|5/10/2016||Margaret M Mccarthy||EVP||Sell||39,169||$114.45||$4,482,892.05||56,240|| |
|5/3/2016||Mark T Bertolini||CEO||Sell||33,510||$114.00||$3,820,140.00||496,588|| |
|3/15/2016||Gary W Loveman||EVP||Buy||8,970||$111.45||$999,706.50||9,605|| |
|2/22/2016||Molly Joel Coye||Director||Sell||1,175||$106.28||$124,879.00||8,104|| |
|12/23/2015||Margaret M Mccarthy||EVP||Sell||18,373||$109.97||$2,020,478.81||63,515|| |
|12/22/2015||Mark T. Bertolini||CEO||Sell||26,996||$110.00||$2,969,560.00||729,194|| |
|8/14/2015||Joseph M Zubretsky||EVP||Sell||179,087||$118.66||$21,250,463.42|| |
|8/13/2015||Franklin Barbara Hackman||Director||Sell||2,064||$118.47||$244,522.08|| |
|3/31/2015||Joseph M Zubretsky||EVP||Sell||200,000||$107.96||$21,592,000.00|| |
|3/27/2015||Joseph M Zubretsky||EVP||Sell||86,958||$107.24||$9,325,375.92|| |
|3/26/2015||Joseph M Zubretsky||Insider||Sell||162,066||$106.98||$17,337,820.68|| |
|3/26/2015||Margaret M Mccarthy||EVP||Sell||27,670||$106.04||$2,934,126.80|| |
|3/25/2015||Franklin Barbara Hackman||Director||Sell||3,000||$108.75||$326,250.00|| |
|3/17/2015||William James Casazza||VP||Sell||14,000||$105.07||$1,470,980.00|| |
|3/2/2015||Molly Joel Coye||Director||Sell||2,500||$100.27||$250,675.00|| |
|2/10/2015||Rajan Parmeswar||VP||Sell||5,300||$95.60||$506,680.00|| |
|6/16/2014||Molly Joel Coye||Director||Sell||1,650||$80.60||$132,990.00|| |
|6/12/2014||William James Casazza||VP||Sell||15,906||$80.58||$1,281,705.48|| |
|5/27/2014||Franklin Barbara Hackman||Director||Sell||2,665||$77.26||$205,897.90|| |
|2/19/2014||Rajan Parmeswar||VP||Sell||3,600||$69.46||$250,056.00||3,829|| |
|12/30/2013||Mark Bertolini||CEO||Sell||130,272||$68.08||$8,868,917.76||526,938|| |
|12/27/2013||William James Casazza||VP||Sell||10,299||$68.25||$702,906.75||33,903|| |
|8/26/2013||William James Casazza||VP||Sell||15,745||$64.66||$1,018,071.70||33,903|| |
|6/18/2013||William James Casazza||VP||Sell||40,598||$62.00||$2,517,076.00|| |
|5/21/2013||Molly Joel Coye||Director||Sell||2,000||$60.38||$120,760.00|| |
|5/20/2013||Joseph P Newhouse||Director||Sell||14,000||$59.15||$828,100.00|| |
|5/15/2013||Rajan Parmeswar||VP||Sell||1,435||$60.13||$86,286.55|| |
|2/6/2013||Karen Rohan||VP||Buy||4,035||$49.53||$199,853.55|| |
Aetna (NYSE AET) News Headlines
Aetna (NYSE:AET) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aetna (NYSE:AET) Income Statement, Balance Sheet and Cash Flow Statement
Aetna (NYSE AET) Stock Chart for Tuesday, March, 20, 2018